Shulamit Ron-Bigger sold $1.4M of AKTS
Chief Operating Officer at Aktis Oncology, Inc.. 50,000 shares at an average of $27.75, traded Jul 8, 2026, filed Jul 10, 2026.
Score components
- +20RoleCOO
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-300163, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | MOption exercise Common Stock | +50,000 | $3.66 | $183k | 50,000 | Jul 10, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock | -15,800 | $27.13 | $429k | 34,200 | Jul 10, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock | -30,000 | $27.94 | $838k | 4,200 | Jul 10, 2026 |
| Jul 8, 2026 | SOpen-market sale Common Stock | -4,200 | $28.75 | $121k | 0 | Jul 10, 2026 |
| Jul 8, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 217,888 | Jul 10, 2026 |
Related signals
Other insiders at Aktis Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $259k 12,500 shares | -100% | |
| 45Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $119k 4,856 shares | -100% | |
| 43Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $77k 3,065 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $1.4M 50,000 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Ansbert Gadicke owner | $20M 1,112,777 shares | +12% | |
| 60Notable | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.p. owner | $20M 1,112,777 shares | +12% | |
| 68Notable | Aktis Oncology, Inc. | Todd Foley director, owner | $4.2M 232,870 shares | +6% | |
| 75Notable | Aktis Oncology, Inc. | EcoR1 Capital, LLC director | $40M 2,222,222 shares | +98% | |
| 68Notable | Aktis Oncology, Inc. | Helen Susan Kim director, owner | $15M 835,000 shares | +17% | |
| 60Notable | Aktis Oncology, Inc. | Vida Ventures II, LLC owner | $15M 835,000 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.